In celebration of National Recovery Month, Avenues Recovery at Clarksville has announced an exciting upcoming ...

Approximately 385,000 needlestick and sharps-related injuries among healthcare workers in the U.S. are projected annually by ...

Eli Lilly and Company (NYSE: LLY) today announced a $1 billion expansion of its Limerick, Ireland, manufacturing site to ...

In the ever-evolving landscape of healthcare and pharmaceuticals, clinical research is pivotal in developing new treatments, ...

The Spero Clinic, an Arkansas-based treatment facility specializing in neurological rehabilitation, shares its breakthrough ...

Over the course of 15 phenomenal years, the PM Society Digital Awards have become an unmissable sellout event in the healthcare marketing calendar. Every year provides a new opportunity for agencies ...

The True Colours of Atopic Dermatitis” campaign is aimed at raising awareness of the physical symptoms and emotional impact of this highly prevalent chronic skin condition – affecting an estimated 2% ...

Chapin will work closely with CEO Mac McKellar to oversee the company's strategic initiatives, bringing his extensive ...

Artificial intelligence’s role in disease modeling could be transformative. Its ability to analyze massive datasets rapidly, ...

The developers of sustained acoustic medicine for soft tissue healing will demonstrate its technology for the world's leading orthopedic surgeons and other medical specialists.TRUMBULL, CT / ...

Moberg Pharma AB (OMX: MOB) announces that the company has received information about clinical cure in a subset of patients in the ongoing North American Phase 3 study for MOB-015 against nail fungus.

HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist with the potential to treat a wide range of cancers in combination with other immunotherapiesCancer Research UK’s Centre for ...